Gross margin trends and ability to maintain pricing power against larger competitors like McKesson, AmerisourceBergen, and Cardinal Health
Working capital management and cash conversion cycle - critical given 0.86 current ratio and negative free cash flow
Customer concentration risk and contract renewals with major hospital systems or pharmacy chains
Debt refinancing ability and covenant compliance given negative equity position and distressed balance sheet
low-to-moderate - Healthcare spending is relatively non-discretionary and continues through economic cycles, but elective procedures and certain specialty drug volumes can decline during recessions. Hospital utilization rates and patient volumes affect distributor throughput. The company's financial distress makes it more vulnerable to any demand softness that pressures already-thin margins.
High sensitivity given distressed financial position. Rising interest rates increase financing costs on working capital lines and any debt refinancing, which is particularly damaging given negative operating margins. Higher rates also reduce valuation multiples for unprofitable companies and make restructuring more expensive. The negative equity position suggests significant debt burden relative to asset base.
Industry consolidation among larger distributors (McKesson, AmerisourceBergen, Cardinal Health control ~90% of market) creates pricing pressure and limits growth opportunities for smaller players
Pharmaceutical pricing reform and potential government intervention in drug pricing could compress distributor margins further
Direct-to-provider distribution models by manufacturers (bypassing distributors) and vertical integration by pharmacy benefit managers threaten traditional distribution economics
distressed/special situations - The severe financial deterioration, negative equity, and 67% stock decline attract distressed debt investors, bankruptcy specialists, and high-risk equity traders betting on restructuring outcomes rather than fundamental business performance. Traditional value or growth investors would avoid given lack of profitability and balance sheet impairment. Extremely high risk/reward profile suitable only for sophisticated investors with distressed credit expertise.
Trend
+69.2% vs SMA 50 · +576.8% vs SMA 200
Momentum
Heavy distribution on elevated volume — institutions appear to be exiting. Squeeze setups unlikely while selling pressure persists.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2024 | $10.7B $10.5B–$10.9B | — | $1.50 | — | ±3% | Moderate3 |
FY2025 | $2.8B $2.7B–$2.8B | ▼ -74.1% | $1.01 | ▼ -32.2% | ±4% | Moderate4 |
FY2026(current) | $2.6B $2.5B–$2.6B | ▼ -6.8% | $0.45 | ▼ -55.5% | ±49% | Moderate4 |
INSTITUTIONAL OWNERSHIP
ACH News
About
No description available.
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
ACH◀ | $2.91 | +0.00% | $223M | — | — | -3984.9% | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.96% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -2.64% | — | 50.3 | +398824.8% | -4071.2% | 1500 |